RecruitingNCT07379827

Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

Effectiveness and Adverse-effect Switch Evaluation

Sponsor

Bristol-Myers Squibb

Enrollment

1,500 participants

Start Date

Feb 26, 2026

Study Type

OBSERVATIONAL

Conditions

Schizophrenia

Summary

The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This real-world study tracks the effectiveness and side effects of xanomeline and trospium chloride (brand name KarXT), a newly approved antipsychotic medication, in adults with schizophrenia who are switching from or adding to their current antipsychotic treatment. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of schizophrenia - Your doctor has already decided — independent of this study — to treat you with KarXT - You are either starting KarXT and intending to stop your prior medication, or switching to KarXT from a stable regimen of another antipsychotic **You may NOT be eligible if...** - You have not been prescribed KarXT by your doctor as part of your normal clinical care - You are unwilling to follow the study's clinical care and follow-up requirements Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGXanomeline and trospium chloride (KarXT)

According to the product label

Locations(45)

Local Institution - 0009

Bryant, Arkansas, United States

Local Institution - 0003

Anaheim, California, United States

Local Institution - 0039

Chino, California, United States

Local Institution - 0012

La Palma, California, United States

Local Institution - 0043

Oceanside, California, United States

Local Institution - 0028

Stanford, California, United States

Local Institution - 0005

Bonita Springs, Florida, United States

Local Institution - 0019

Hialeah, Florida, United States

Local Institution - 0030

Homestead, Florida, United States

Local Institution - 0029

Kendall, Florida, United States

Local Institution - 0032

Miami, Florida, United States

Banyan Behavioal Care Program - CSU

Miami, Florida, United States

Local Institution - 0007

Miami, Florida, United States

Local Institution - 0006

Miami, Florida, United States

Local Institution - 0023

Orange City, Florida, United States

Local Institution - 0040

Orlando, Florida, United States

Local Institution - 0025

Atlanta, Georgia, United States

Local Institution - 0044

Marietta, Georgia, United States

Local Institution - 0014

Bloomfield Township, Michigan, United States

Local Institution - 0036

Detroit, Michigan, United States

Local Institution - 0034

Apple Valley, Minnesota, United States

Local Institution - 0041

Lincoln, Nebraska, United States

Local Institution - 0037

Buffalo, New York, United States

Local Institution - 0004

Monsey, New York, United States

Local Institution - 0038

Rochester, New York, United States

Local Institution - 0020

White Plains, New York, United States

Local Institution - 0042

Cary, North Carolina, United States

PPD Virtual - PPD - US

Wilmington, North Carolina, United States

Local Institution - 0031

Mason, Ohio, United States

Local Institution - 0027

Oklahoma City, Oklahoma, United States

Local Institution - 0015

Philadelphia, Pennsylvania, United States

Psychiatric Consultants, Pc

Franklin, Tennessee, United States

Local Institution - 0016

Austin, Texas, United States

Local Institution - 0021

Fort Worth, Texas, United States

Local Institution - 0033

Houston, Texas, United States

Local Institution - 0026

Houston, Texas, United States

Local Institution - 0022

Houston, Texas, United States

Local Institution - 0010

Houston, Texas, United States

Local Institution - 0024

Houston, Texas, United States

Local Institution - 0017

Irving, Texas, United States

Local Institution - 0013

McKinney, Texas, United States

Local Institution - 0008

Richmond, Texas, United States

Local Institution - 0035

San Antonio, Texas, United States

Local Institution - 0018

Stafford, Texas, United States

Local Institution - 0045

Petersburg, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07379827

Related Trials

Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

NCT074679937 locations

Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

NCT0710109418 locations

A Study to Evaluate the Effect of KarXT on Urological Safety

NCT0722187714 locations

Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine

NCT071858156 locations

Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia

NCT057785911 location